MedTrace Logo

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

NCT00955799 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 455

Last updated 2012-11-28

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.

Conditions

  • Subjective Tinnitus

Interventions

DRUG

Neramexane mesylate

Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day

DRUG

Placebo

Double-blind treatment period of 29 weeks placebo

Sponsors & Collaborators

  • Merz Pharmaceuticals GmbH

    lead INDUSTRY

Principal Investigators

  • Medical Expert · Merz Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • United States
  • Austria
  • Brazil
  • Germany
  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00955799 on ClinicalTrials.gov